Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06073769Recruiting
Safety study of oral azacitidine for AML in Korea
This study is monitoring the safety of the drug oral azacitidine (also called Onureg) when given as maintenance therapy to adults with acute myeloid leukemia (AML). It is designed to track how well patients tolerate the medicine in real-world use in Korea.
SeoulAges 19 years+ - NCT07671209Recruiting
Cancer care support for patients with leukemia
This trial studies how screening for social needs (like housing, food, or transportation) and offering early help can improve care for adults with leukemia. It is for patients newly referred to a leukemia clinic.
Boston, MassachusettsAges 18 years+ - NCT06420063RecruitingPhase 1/Phase 2
Two-step CAR-T therapy for AML with CD33/CD123
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Beijing, Beijing MunicipalityAges 6–90 - NCT07651176Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy approaches for newly diagnosed AML
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
Hangzhou, ZhejiangAges 18–65 - NCT07651163Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy regimens for newly diagnosed blood cancer
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hangzhou, ZhejiangAges 15–65 - NCT07652905RecruitingPhase 2
CM336 with Isa-VR for newly diagnosed plasma cell leukemia
This trial tests a new combination treatment for people who have just been diagnosed with primary plasma cell leukemia. The treatment includes a study drug called CM336 along with other cancer-fighting medicines. It aims to see if this combination helps control the disease.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT07638007Recruiting
How targeted therapy affects thinking and memory in blood cancer
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
Rochester, New YorkAges 18 years+ - NCT07645469RecruitingPhase 1
WT1-targeting T cells with azacitidine for AML
This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.
Seattle, WashingtonAges 18 years+ - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT06696833RecruitingEarly Phase 1
CD19-targeted CAR-T cell therapy for relapsed B-ALL
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
Suzhou, China, JiangsuAges 14 years+ - NCT07627568Recruiting
Studying a New Drug for Leukemia After Stem Cell Transplant
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
Freiburg im BreisgauAges 18 years+ - NCT07616921Recruiting
Home Exercise Program for Heart Health During Leukemia Transplant
This study tests whether doing gentle exercise at home can help protect your heart during stem cell transplant treatment for acute myeloid leukemia (a type of blood cancer). You'll use a smartphone app to guide daily workouts designed to be safe and manageable during your treatment.
Seattle, WashingtonAges 18 years+ - NCT07616089RecruitingPhase 1
Study of a new pill for advanced blood cancers
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
New Haven, ConnecticutAges 18–80 - NCT07604064RecruitingPhase 2
IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Tokyo and Other Japanese CitiesAges 18 years+ - NCT07602088Recruiting
Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
BucharestAges 18 years+ - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07588594Recruiting
Thiotepa-Based Stem Cell Transplant for Chronic Myelomonocytic Leukemia
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
BeijingAges 18 years+ - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06722638Recruiting
Virtual reality for lumbar punctures in leukemia
This study tests if using a virtual reality headset during a lumbar puncture (a spinal tap) can help children feel less pain and anxiety. It is for children with acute lymphoblastic leukemia (ALL) or lymphoma who are in the maintenance phase of treatment.
Washington D.C., District of ColumbiaAges 7 years+
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.